论文部分内容阅读
We present an integrated microfluidic device to isolate,capture and culture cancer cells from human peripheral blood,and demonstrate its utility in anti-cancer drug screening.The microfluidic platform consists of a combination of microfluidic I deterministic lateral displacement(DLD)array and a microfluidic channel with sieve-like cell trapping structures2.The DLD structure was used to rapidly separate cancer cells from whole blood samples,utilizing the size differences between the cancer cells and normal blood cells.After sample enrichment from the DLD array,cells flow through the sieve-like microfluidic channel and sequentially fill the trap positions,in order to achieve high efficiency marker free cell capture.In addition,we have successfully performed the subsequent cell culture and anti-cancer drug screening in this device.Using this device to isolate MCF-7 breast cancer cell from spiked blood samples,we achieved a high processing throughput of 2 mL/min with 80% capture yield.Different anti-cancer drugs(MMC and TAM)were tested in the microfluidic system,and their cytotoxic effects on MCF-7 breast cancer cells were compared,indicating the integrated device is a useful platform for drug sensitivity screening.The whole process,including cancer cell isolation,capture,culture and drug screening,was performed within an integrated microfluidic device with simple operation,and greatly preserved the viability of cancer cells.Our integrated microfluidic system has great potential to supplement existing CTC isolation and enumeration schemes.The rapid isolation of cancer cells combined with efficient drug sensitivity testing capability,suggesting that the microfluidic device is an attractive platform for the development of personalized medicine in future cancer diagnosis.